BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Wall Street 'Reolysin' Value; Oncolytics Soars on Phase III
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Wall Street 'Reolysin' Value; Oncolytics Soars on Phase III
Dec. 14, 2012
By
Randy Osborne
No Comments
Stock buyers hardly cared that Oncolytics Biotech Inc.'s early Phase III results with Reolysin, its reovirus variant for head and neck cancer, lacked survival data and slipped on part of its endpoint – the rest was just too good.
BioWorld